Genmab Announces 23% Year-Over-Year Sales Growth for DARZALEX in 2025

Genmab reported a 23% year-over-year increase in global sales of its monoclonal antibody DARZALEX (daratumumab) for 2025, reaching $4.1 billion, driven by expanded use in multiple myeloma and ongoing international market penetration. The results were disclosed in the company’s Q4 2025 earnings report released January 21, 2026. The growth reflects continued demand across key markets, including the United States, Europe, and Asia-Pacific, despite increased competition from biosimilars. Genmab reiterated its guidance for sustained revenue momentum through 2026, citing new clinical data supporting DARZALEX’s role in frontline therapy. The drug remains a cornerstone of the company’s portfolio, contributing 68% of total 2025 revenues. Genmab’s shares rose 3.2% in after-hours trading following the announcement.